Dr. Charles J. Fisher, Jr. Joins Aethlon Medical’s Board of Directors

[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

Dr. Charles J. Fisher qualifies as an independent director under the Nasdaq Rules, and his appointment to Aethlon Medical Inc. fills an open Board seat.

Dr. Fisher is a physician scientist with a distinguished career in both academia and industry spanning over 30 years. As an experienced executive and entrepreneur, he brings a successful track record of developing operating strategies that take products to markets, drive sales and build profitable companies. Prior to joining industry, Dr. Fisher served as Head of the Section of Critical Care Medicine at The Cleveland Clinic Foundation

Jim Joyce, CEO of Aethlon said, “We are honored to have Chuck join our Board of Directors and look forward to leveraging his proven expertise in advancing first-in-class therapies to market.”

Dr. Fisher’s research in sepsis, inflammation, host defense and endothelial dysfunction led to his recruitment to Eli Lilly & Co., where he led the Xigris (activated Protein C) Global Product Team and successfully registered the first drug approved for the treatment of sepsis. Subsequently, he was recruited to Abbott Laboratories as Divisional Vice President for Global Pharmaceutical Research and Development (GPRD), where, among other accomplishments, he guided the registration of Humira (the first fully humanized anti-TNF mab).

He was Chief Medical Officer and Executive Vice President of Cardiome Pharma Corp. where he led the team that invented, developed, registered vernakalant, a novel, first in class, multi-ion channel drug for atrial fibrillation (Brinavess). He currently serves as Executive Chairman of CytoPherx, Inc., a medical device company with novel IP focused on modulating acute and chronic inflammation.

In addition, Fisher is a multi-tour combat veteran, with extensive leadership experience in special operations. He has served as a member of the Defense Science Research Council and on DARPA panels, including one focused on universal host defense.